Advanced search
Publication Cover
Cutaneous and Ocular Toxicology Volume 38, 2019 - Issue 1
Submit an article Journal homepage
649
Views
18
CrossRef citations to date
0
Altmetric
Original Article

The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria

Ersoy AcerDepartment of Dermatology, Eskişehir Osmangazi University, Eskişehir, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6041-6636
ORCID Icon,
Hilal Kaya ErdoganDepartment of Dermatology, Eskişehir Osmangazi University, Eskişehir, TurkeyORCID Iconhttps://orcid.org/0000-0002-8172-1920
ORCID Icon,
Nihan Yüksel ÇanakçıDepartment of Dermatology, Eskişehir Osmangazi University, Eskişehir, TurkeyORCID Iconhttps://orcid.org/0000-0002-3299-0876
ORCID Icon &
Zeynep Nurhan SaracogluDepartment of Dermatology, Eskişehir Osmangazi University, Eskişehir, TurkeyORCID Iconhttps://orcid.org/0000-0002-9116-2288
ORCID Icon
Pages 5-8 | Received 16 Apr 2018, Accepted 26 Jun 2018, Published online: 10 Sep 2018
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

Purpose

The mechanism of action of omalizumab in chronic spontaneous urticaria (CSU) is not exactly known. In previous studies, d-dimer which is a fibrin-degradation product and interleukin-31 which has a role in inflammation were found to be decreased in patients with chronic urticaria treated with omalizumab. However, to our knowledge, there is no study on the effects of omalizumab on the ratio of neutrophil to lymphocyte (NLR) and the ratio of platelet to lymphocyte (PLR) which are inflammatory parameters in patients with CSU in the PubMed database. In this study, we aimed to evaluate the effects of omalizumab on hematological and inflammatory parameters in patients with CSU.

Materials and Methods

One hundred six CSU patients treated with omalizumab were evaluated retrospectively. Complete blood count (CBC) and C-reactive protein (CRP) levels before treatment and at the third month of treatment were recorded. NLR and PLR were calculated from the CBC results. CBC parameters, CRP levels, NLR and PLR of the patients before treatment and at the end of third month of treatment were compared.

Results

There was a significant decrease in white blood cell count, platelet count, neutrophil count, CRP level, NLR and PLR and a significant increase in mean platelet volume and eosinophil count with omalizumab treatment in CSU patients (p < 0.05). Basophil count increased; but there was no statistically significant difference (p = 0.293).

Conclusion

This study shows that omalizumab has not only anti Ig E effect, but also it may have inhibitory effects on inflammation and coagulation in patients with CSU.

Further prospective studies are warranted in order to evaluate the effect of omalizumab on hematological and inflammatory parameters and correlation between omalizumab response rate and these inflammatory parameters in patients with CSU.

Disclosure statement

No potential conflict of interest was reported by the authors.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,568.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.